Carisma Therapeutics, Inc. (CARM)
OTCMKTS · Delayed Price · Currency is USD
0.0023
0.00 (0.00%)
At close: Aug 18, 2026
Carisma Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 52.63 | 19.63 | 14.92 | 9.83 | - | - | |
Revenue Growth | 159.68% | 31.59% | 51.71% | - | - | - |
Cost of Revenue | 27.36 | 59.67 | 74.13 | 56.62 | 34.39 | - |
Gross Profit | 25.28 | -40.04 | -59.21 | -46.78 | -34.39 | - |
Selling, General & Admin | 12.43 | 20.14 | 29.53 | 9.38 | 6.41 | 5.09 |
Research & Development | - | - | - | - | - | 23.29 |
Operating Expenses | 12.43 | 20.14 | 29.53 | 9.38 | 6.41 | 28.38 |
Operating Income | 12.85 | -60.18 | -88.73 | -56.16 | -40.79 | -28.38 |
Interest Expense | - | - | - | -3.15 | - | - |
Interest & Investment Income | 1.3 | 1.7 | 1.94 | - | 0.01 | 0.03 |
Other Non Operating Income (Expenses) | 0.04 | - | -0.08 | -1.92 | - | - |
EBT Excluding Unusual Items | 14.19 | -58.48 | -86.88 | -61.23 | -40.78 | -28.35 |
Merger & Restructuring Charges | -2 | -2 | - | - | - | - |
Pretax Income | 8.04 | -60.48 | -86.88 | -61.23 | -40.78 | -28.35 |
Net Income | 8.04 | -60.48 | -86.88 | -61.23 | -40.78 | -28.35 |
Net Income to Common | 8.04 | -60.48 | -86.88 | -61.23 | -40.78 | -28.35 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 42 | 41 | 34 | 2 | 1 | 1 |
Shares Outstanding (Diluted) | 42 | 41 | 34 | 2 | 1 | 1 |
Shares Change | 1.84% | 23.66% | 1475.33% | 96.30% | 1.95% | - |
EPS (Basic) | 0.19 | -1.46 | -2.59 | -28.77 | -37.62 | -26.66 |
EPS (Diluted) | 0.19 | -1.46 | -2.59 | -28.77 | -37.62 | -26.66 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Free Cash Flow | -22.42 | -60.04 | -82.31 | -9.78 | -39.2 | -27.45 |
Free Cash Flow Per Share | -0.54 | -1.45 | -2.46 | -4.59 | -36.16 | -25.82 |
Gross Margin | 48.03% | -203.96% | - | - | - | - |
Operating Margin | 24.41% | -306.54% | -594.75% | -571.10% | - | - |
Profit Margin | 15.28% | -308.05% | -582.34% | -622.60% | - | - |
Free Cash Flow Margin | -42.59% | -305.83% | -551.71% | -99.41% | - | - |
EBITDA | 14.18 | -56.83 | -85.89 | -54.27 | -40.11 | -27.93 |
EBITDA Margin | 26.94% | -289.45% | - | - | - | - |
D&A For EBITDA | 1.33 | 3.35 | 2.84 | 1.89 | 0.68 | 0.45 |
EBIT | 12.85 | -60.18 | -88.73 | -56.16 | -40.79 | -28.38 |